Rohto Pharmaceutical Co., Ltd. (TSE:4527) acquired Olympus RMS Co., Ltd. from Olympus Corporation (TSE:7733) on March 23, 2021. Olympus RMS will continue to operate as a leading regenerative medicine technology company as part of Rohto Pharmaceutical, engaged in manufacturing and marketing of pharmaceuticals and cosmetics products. Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. acted as financial advisor to Olympus Corporation.

Rohto Pharmaceutical Co., Ltd. (TSE:4527) completed the acquisition of Olympus RMS Co., Ltd. from Olympus Corporation (TSE:7733) on March 23, 2021.